Florida initiates clinical trial testing ivermectin against cancer

The state of Florida, led by Governor Ron DeSantis, has launched an official Phase‑2 clinical trial to evaluate whether the antiparasitic drug ivermectin can affect cancer growth. The study, registered as NCT07487805 (ICONIC), will enroll about 80 adult patients with solid tumours who are already receiving immune‑checkpoint inhibitor therapy. Participants will be randomized to receive either an intermediate dose (200 µg/kg) or a high dose (400 µg/kg) of ivermectin orally for three consecutive days each week over four weeks, while continuing their immunotherapy.

The primary endpoint is the change in activated CD8‑T cells (Ki‑67⁺ HLA‑DR⁺ non‑naïve CD8⁺ T‑cells) after two weeks, with secondary measures of safety (grade ≥ 3 adverse events) and cytokine alterations. Funding comes from the Florida Cancer Innovation Fund, initially allocating $60 million for innovative cancer research, including drug‑repurposing efforts. Critics argue the trial is unnecessary and risky because ivermectin is not FDA‑approved for cancer treatment, while supporters cite pre‑clinical data suggesting possible anti‑angiogenic and immunomodulatory effects. The study is set to start in September and conclude by the end of 2027, and its results will be watched both nationally and internationally.